Table 6 Clinical characteristics and treatment of Behçet’s Disease according to disease activity (n = 30)
From: Assessment of sleep quality, anxiety, depression, and quality of life in Behçet’s disease
Active BD N = 13 | Inactive BD N = 17 | P-value | |
|---|---|---|---|
Clinical data | |||
Fever | 9 (69%) | 1 (5%) | < 0.001* |
Fatigue | 11 (84%) | 2 (11%) | < 0.001* |
Weight loss | 3 (23%) | 1 (5%) | 0.029* |
Oral ulcer | 5 (38%) | 6 (35%) | 0.579 |
Genital ulcer | 5 (38%) | 6 (35%) | 0.579 |
.Skin lesion | 1 (7%) | 3 (17%) | 0.041* |
Arthritis/arthralgia | 2 (15%) | 1 (5%) | 0.397 |
Ophthalmic | 3 (23%) | 3 (17%) | 0.531 |
Vascular | 3 (23%) | 0 (0%) | 0.070 |
GIT | 1 (7%) | 1 (5%) | 0.068 |
Pulmonary | 5 (38%) | 1 (5%) | 0.04* |
Disease Duration | 8.34 ± 5.18 | 5.85 ± 2.73 | 0.029* |
BDCAF | 4.15 ± 1.28 | 1.05 ± 0.66 | < 0.001* |
Clinical Severity score | 5.62 ± 1.26 | 0.18 ± 0.39 | < 0.001* |
VDI | 4.08 ± 2.13 | 0.53 ± 0.62 | 0.002* |
Treatment | |||
Colchicine | 3 (23%) | 0 (0%) | 0.07 |
Steroid | 8 (61%) | 5 (29%) | 0.082 |
Azathioprine | 8 (61%) | 6 (35%) | 0.145 |
Anti-TNF | 1 (7%) | 0 (0%) | 0.433 |
Cyclophosphamide | 1 (7%) | 0 (0%) | 0.433 |
No Medication | 0 (0%) | 6 (35%) | 0.021* |